EUVIMEDEUVIMED entdecken
Crossref

c-MET tyrosine kinase inhibitors reverse multidrug resistance in breast cancer cells by targeting ABCG2 transporter

Somayeh Nazari, Fatemeh Mosaffa, Alireza Poustforoosh, Luciano Saso, Omidreza Firuzi, Fatemeh Moosavi iD

Journal of Pharmacy and Pharmacology · 2025

DOI: 10.1093/jpp/rgaf008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Somayeh Nazari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily G, Member 2, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Shiraz University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Overcoming multidrug resistance (MDR), which is often caused by the overexpression of ATP binding cassette (ABC) transporters in cancer cells remains a major challenge for cancer treatment. Receptor tyrosine kinase inhibitors have demonstrated potential in reversing MDR. This study aimed to investigate the effects of c-MET RTKIs on the reversal of MDR induced by ABCG2 in breast cancer cells.

Methods

MTT assay was employed to assess antiproliferative activity of c-MET inhibitors, including cabozantinib, crizotinib, and PHA665752. The accumulation of the fluorescent probe mitoxantrone was evaluated by flow cytometry. The drug–drug interaction in combination treatments was analyzed using CalcuSyn software.

Results

The combination of cabozantinib, crizotinib, and PHA665752 with mitoxantrone resulted in synergistic effects in MDR cells. This was demonstrated by the mean CI values of 0.32 ± 0.07, 0.53 ± 0.05, and 0.59 ± 0.03, respectively. In the same cells, c-MET inhibitors enhanced the accumulation of mitoxantrone, with accumulation ratios ranging from 1.6 to 3.8, while no change was found in parental MCF-7 cells. Computational analysis revealed that the drug-binding region of ABCG2 transporters could be a viable target for these compounds. Conclusion c-MET inhibitors hold potential as effective agents for reversing MDR in ABCG2-medicated drug-resistant cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP Binding Cassette Transporter, Subfamily G, Member 2Drug Resistance, NeoplasmProto-Oncogene Proteins c-metBreast NeoplasmsProtein Kinase InhibitorsDrug Resistance, MultipleNeoplasm ProteinsHumansFemaleMitoxantroneCrizotinibCell Line, TumorPyridinesMCF-7 CellsAnilidesAntineoplastic AgentsCell ProliferationDrug SynergismIndolesMolecular Docking SimulationTyrosine Kinase InhibitorsHeterocyclic Compounds, 4 or More RingsDiketopiperazines

Stichwörter der Autor:innen

ABCG2 transportercombination treatmentdrug resistancereversal agenttyrosine kinase inhibitors

Substanzen

ATP Binding Cassette Transporter, Subfamily G, Member 2Proto-Oncogene Proteins c-metABCG2 protein, humanProtein Kinase InhibitorsNeoplasm ProteinsMitoxantroneCrizotinibPyridinescabozantinibAnilides

Autor:innen und Institutionen

  • Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, P. le Aldo Moro 5, 00185 Rome, Italy.

ORCID-Profile: Fatemeh Moosavi

Förderung

  • Shiraz University of Medical Sciences

Zitieren

APA

Nazari, S., Mosaffa, F., Poustforoosh, A., Saso, L., Firuzi, O., & Moosavi, F. (2025). c-MET tyrosine kinase inhibitors reverse multidrug resistance in breast cancer cells by targeting ABCG2 transporter. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf008

Vancouver

Nazari S, Mosaffa F, Poustforoosh A, Saso L, Firuzi O, Moosavi F. c-MET tyrosine kinase inhibitors reverse multidrug resistance in breast cancer cells by targeting ABCG2 transporter. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgaf008

BibTeX
@article{Nazari2025,
  author = {Nazari, Somayeh and Mosaffa, Fatemeh and Poustforoosh, Alireza and Saso, Luciano and Firuzi, Omidreza and Moosavi, Fatemeh},
  title = {c-MET tyrosine kinase inhibitors reverse multidrug resistance in breast cancer cells by targeting ABCG2 transporter},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2025},
  doi = {10.1093/jpp/rgaf008}
}
Kostenlos starten →